Affiliation: South Carolina Oncology Associates
- A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancerR E Smith
South Carolina Oncology Associates, 1301 Taylor, Suite 1A, Columbia, SC 29201, USA
Br J Cancer 88:1851-8. 2003..Darbepoetin alpha effectively increases haemoglobin concentration when given QW, Q3W, or Q4W. Less-frequent administration may benefit patients with chronic anaemia of cancer and their caregivers alike...
- Applications of darbepoietin-alpha, a novel erythropoiesis-stimulating protein, in oncologyRobert Smith
South Carolina Oncology Associates, Columbia, South Carolina 29201, USA
Curr Opin Hematol 9:228-33. 2002..Confirmation of improved response and response times with this novel therapy may enable patients with cancer to benefit more rapidly...
- Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumorsRobert E Smith
South Carolina Oncology Associates, Columbia, 29210, USA
J Natl Compr Canc Netw 4:649-58. 2006..Because of this trend toward more intensive treatment of patients with cancer, proactive steps should be taken to minimize the risk for myelosuppression and its complications while optimizing the relative dose intensity...
- The clinical and economic burden of anemiaRobert E Smith
South Carolina Oncology Associates, 166 Stoneridge Dr, Columbia, SC 29210, USA
Am J Manag Care 16:S59-66. 2010..Clinicians need to be more cognizant of the symptoms of anemia and more vigilant in its treatment to ensure better outcomes both clinically and financially...
- Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survivalRobert E Smith
South Carolina Cancer Center, and South Carolina Oncology Associates, Columbia, South Carolina 29201, USA
J Support Oncol 1:249-56, 258-9; discussion 257-8. 2003..In the next issue, Dr. Smith will discuss the possible role of erythropoietic agents in neuroprotection and neurotherapy, including cognitive dysfunction in cancer patients...
- Erythropoietic agents in the management of cancer patients. Part 2: studies on their role in neuroprotection and neurotherapyRobert E Smith
South Carolina Cancer Center, Columbia, South Carolina, USA
J Support Oncol 2:39-49. 2004..The current state of knowledge about the use of erythropoietic agents for neuroprotection or the treatment of neurologic syndromes is described...
- Practitioners' practical model for managing cancer-related anemiaRobert E Smith
South Carolina Oncology Associates, Columbia 29201, USA
Oncology (Williston Park) 16:55-63. 2002....
- Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled studyRobert E Smith
South Carolina Oncology Associates, Columbia, SC, USA
J Clin Oncol 26:1040-50. 2008..The efficacy and safety of darbepoetin alpha (DA) for treating patients with active cancer and anemia not receiving or planning to receive cytotoxic chemotherapy or myelosuppressive radiotherapy was evaluated...
- Clarifying the use of erythropoietic agentsRobert E Smith
J Support Oncol 2:200, 202; author reply 202. 2004
- Letrozole for the management of breast cancerPaul E Goss
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, 5 303, Toronto, Ontario, M5G 2M9, Canada
Expert Rev Anticancer Ther 2:249-60. 2002..Nevertheless, the superior clinical efficacy and survival data of letrozole suggest that it has the potential to displace tamoxifen as the gold standard in breast cancer treatment in the coming years...
- Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancerThomas E Delea
Policy Analysis Inc, 4 Davis Court, Brookline, MA 02245, USA
Am J Manag Care 12:374-86. 2006..To estimate the cost-effectiveness of extended adjuvant letrozole in postmenopausal women with early breast cancer and estrogen or progesterone receptor-positive tumors who had completed 5 years of adjuvant tamoxifen...
- Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studiesEdgardo Rivera
University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Clin Breast Cancer 7:33-41. 2006..Many oncologists are aware of this trend toward the more intensive treatment of patients with cancer and take proactive steps to minimize the risk of myelosuppression and its complications...
- Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemiaJon D Herrington
Scott and White Memorial Hospital, Department of Clinical Pharmacy, Temple, TX 76508, USA
Am J Health Syst Pharm 62:54-62. 2005..The patterns of use and effectiveness of therapy with darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia (CIA) in hospital outpatient and community settings were evaluated...
- Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfaKenneth R Meehan
Bone Marrow Transplant Program, Section of Hematology Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
Clin Drug Investig 26:593-601. 2006..This study set out to identify the resource use and time commitment associated with treatment of anaemia with erythropoietic therapy, for both haematology/oncology clinics and patients...
- Spitting into the wind: the irony of treating chronic diseaseRobert E Smith
Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, AL 36849 5502, USA
J Am Pharm Assoc (2003) 46:397-400. 2006..To propose a paradigm shift in the role of the pharmacist by encouraging pharmacists' involvement in the achievement and maintenance of healthy lifestyles in their patients, thus reducing the need for long-term medications...